Search for: "Pennsylvania Services Corp. v. Texas Eastern"
Results 1 - 20
of 31
Sorted by Relevance
|
Sort by Date
19 Jan 2018, 10:48 am
FBL Financial Services, Inc. and University of Texas Southwestern Medical Center v Nassar indicate that a “motivating factor” test is inappropriate. [read post]
5 Apr 2018, 7:55 pm
No. 01-17-00253-CVIN THE COURT OF APPEALS FOR THE FIRST APPELLATE DISTRICT OF TEXAS AT HOUSTON, TEXAS LADANTA D. [read post]
7 Feb 2019, 12:08 pm
Bayer Corp., in the Eastern District of Texas; and United States ex rel. [read post]
19 Nov 2011, 11:34 am
A Texas appeals court says that the court cannot reform a noncompete to eliminate the damages remedy otherwise available through arbitration: Gray Wireline Service, Inc. v. [read post]
2 Oct 2015, 12:49 am
Ceridian Corp. [read post]
15 Jun 2023, 6:17 am
(SD 2/13/2023) – On June 6, 2023, the case was transferred to the Eastern District of Texas and assigned case number 4:23-cv-00516. [read post]
15 Feb 2020, 6:56 am
Galerie Eva Presenhuber Corp. [read post]
2 Oct 2012, 1:08 pm
Sustainable Energy Corp. and John H. [read post]
13 Oct 2021, 9:08 am
District Court for the Eastern District of Pennsylvania Krochalis v. [read post]
13 Oct 2021, 9:08 am
District Court for the Eastern District of Pennsylvania Krochalis v. [read post]
6 Oct 2017, 11:39 pm
In Texas, for example, a collection action is subject to a four-year limitations period under TEX. [read post]
25 Apr 2011, 4:55 am
(IPBiz) US Patents – Lawsuits and strategic steps Despatch Industries – In PV furnace case green patent litigation moves upstream (Green Patent Blog) Heathcote Holdings Corp – False marking Plaintiff’s chosen form not given deference: Heathcote Holdings Corp., Inc. v. [read post]
12 Apr 2023, 6:33 am
See, United States v. [read post]
11 Apr 2008, 9:00 am
No problem…: Lundbeck A/S v Generics UK Ltd & Ors: (IPKat), Exelon (Rivastigmine Tartrate) – Dr Reddy’s and Novartis settle Exelon patent dispute: (Therapeutics Daily), GeneMaker – Codon Devices, Blue Heron Biotechnology settle patent suit over gene synthesis platform: (Patent Docs), Glucophage (Metformin) – Depomed settles patent litigation against IVAX: (SmartBrief), (IP Law360), (GenericsWeb), Lexapro… [read post]
26 Jul 2010, 9:08 am
– Trading Markets.com, July 21, 2010 Consistent with Section 122 of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (“CERCLA”), 42 U.S.C. 9622(d), and 28 CFR 50.7, notice is hereby given that on July 16, 2010, the United States lodged a Consent Decree with 163 defendants (each of which is identified in the proposed Decree) in United States of America v. [read post]
6 Apr 2010, 4:56 am
(GRAY on Claims) District Court E D Texas finds Applied Medical Resources liable for infringement of Covidien’s surgical device patent (Patent Docs) District Court E D Texas limits number of patent claims and prior art references asserted in case: SynQor, Inc v Artesyn Technologies, Inc et al (Docket Report) District Court W D Pennsylvania: Non-practising entity entitled to permanent injunction where infringed patent was the subject of prior exclusive… [read post]
2 Aug 2010, 11:15 am
Click Here Pennsylvania Steel Beam and Concrete Manufacturers Settle Chemical Release Reporting Violations at Lancaster, Williamsport and Denver Plants. [read post]
13 Jun 2013, 7:05 pm
Casey in light of this Court’s ruling that informational requirements further "the State’s legitimate interest of reducing the risk that a woman may elect an abortion, only to discover later, with devastating psychological consequences, that her decision was not fully informed;" (2) whether the Oklahoma Supreme Court erred in interpreting Casey as prohibiting informed consent laws requiring the performance, display and explanation of pre-abortion ultrasounds – an interpretation… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
7 Feb 2008, 10:46 am
The leading case is Kemp v. [read post]
